

1 Aggregation versus Biological Activity in Gold(I) Complexes. An 2 Unexplored Concept

3 Andrea Pinto,[†] Catarina Roma-Rodrigues,[†] Jas S. Ward, Rakesh Puttreddy, Kari Rissanen,
4 Pedro V. Baptista, Alexandra R. Fernandes,* João Carlos Lima, and Laura Rodríguez*



Cite This: <https://doi.org/10.1021/acs.inorgchem.1c02359>



Read Online

ACCESS |



Metrics & More




Article Recommendations



Supporting Information

5 **ABSTRACT:** The aggregation process of a series of mono- and
6 dinuclear gold(I) complexes containing a 4-ethynylaniline ligand
7 and a phosphane at the second coordination position ($\text{PR}_3\text{-Au-C}\equiv$
8 $\text{CC}_6\text{H}_4\text{-NH}_2$, complexes 1–5, and (diphos)(Au-C \equiv CC $_6\text{H}_4$ -
9 NH_2)₂, complexes 6–8), whose biological activity was previously
10 studied by us, has been carefully analyzed through absorption,
11 emission, and NMR spectroscopy, together with dynamic light
12 scattering and small-angle X-ray scattering. These experiments
13 allow us to retrieve information about how the compounds enter
14 the cells. It was observed that all compounds present aggregation in
15 fresh solutions, before biological treatment, and thus they must be
16 entering the cells as aggregates. Inductively coupled plasma atomic
17 emission spectrometry measurements showed that mononuclear
18 complexes are mainly found in the cytosolic fraction; the dinuclear
19 of nuclei and cytoskeleton. Additionally, dinuclear complex 8 affects
20 effect of dinuclear compounds.



complexes are mainly found in a subsequent fraction composed
of nuclei and cytoskeleton. Additionally, dinuclear complex 8 affects

21 ■ INTRODUCTION

22 Gold compounds have a long and important tradition from
23 ancient times, where they were already used in medicine (the
24 so-called Chrysotherapy).¹ At the beginning, gold complexes
25 were widely used for the treatment of several diseases,
26 especially as anti-infectious and anti-tubercular agents, but the
27 treatment of rheumatoid arthritis with a phosphine–gold
28 thiolate complex, auranofin, was a key point in revealing the
29 potential of these types of complexes as metallodrugs.
30 Nowadays, these types of complexes are very well studied
31 because of their potential applications as anticancer agents^{2–10}
32 and even, very recently, because of preliminary promising
33 results in the fight against the SARS-CoV2 virus.^{11,12}
34 Interestingly, gold(I) metallodrugs display better tolerance in
35 *in vivo* studies than platinum derivatives, which are well-known
36 as anticancer agents since the discover of cisplatin.
37 Phosphane–gold(I) alkynyl complexes are among the most
38 studied of the gold(I) complexes reported, with some
39 promising results in the literature for potential anticancer
40 activity.^{9,13–20}

41 The mechanism of action of gold(I) complexes seems to be
42 significantly different from that followed by platinum drugs
43 because gold(I) targets cellular enzymes, while platinum
44 compounds target DNA. Knowledge of the interactions of
45 medicinal gold compounds with proteins is highly relevant to
46 understanding and defining their mechanism of action.

Proteomic and metallomic strategies were successfully
implemented for elucidation of the specific mechanistic
features of anticancer metallodrugs uncovering their physio-
logical processes and molecular targets from the perspective of
a biological system,^{21–23} together with specific techniques
including fluorescence spectroscopy and microscopy, X-ray
fluorescence spectrometry (total reflection X-ray fluorescence),
mass spectrometry, absorption spectroscopy, X-ray crystallog-
raphy, NMR spectroscopy, X-ray absorption spectroscopy,
inductively coupled plasma, and others.^{13,19,21,24,25} These
studies allowed the determination of local metallic structures
participating in the interaction with proteins, speciation of the
complexes, cellular uptake, and biodistribution. Interestingly, it
seems that the binding of metal complexes to proteins might
not alter the protein conformation and the secondary or
tertiary structure of the proteins, with metal binding being
assured by the directional interactions of the metal with
specific residue side chains.²⁶

Received: August 3, 2021




Figure 1. Chemical structures of the biologically active gold(I) complexes studied in this work.




Figure 2. X-ray crystal structures of **1a** (A) and **1b** (B). Color code: yellow, gold; orange, phosphorus; black, carbon; light blue, nitrogen. Hydrogen atoms and solvates have been omitted for clarity.




Figure 3. X-ray crystal structures of **4** (A) and **5** (B). Color code: yellow, gold; orange, phosphorus; black, carbon; light blue, nitrogen. Hydrogen atoms have been omitted for clarity.

In general, it is well accepted that the thioredoxin reductase enzyme appears as the main target of these types of metallodrugs because of the high affinity of gold for thiol and selenol groups,^{5,7} although their mechanism of action is not completely understood yet, and other targets such as aquaporin-3,²⁷ zinc finger proteins [such as poly-(adenosinediphosphate ribose)polymerase-1],²⁸ quadruplex DNA,^{29,30} and other thiolate-dependent enzymes (such as human glutathione reductase, glutathione peroxidase, glutathione-S-transferases, and cysteine protease)⁷ cannot be ignored.

On the other hand, it must be highlighted that gold(I) complexes are well-known to establish gold(I)⋯gold(I) interactions (either intra- or intermolecularly)^{31,32} to yield supramolecular assemblies, which are particularly favored in

aqueous solutions even at very dilute concentrations.^{33–39} This fact indicated that aggregation might be directly involved in the biological mechanism of gold(I) metallodrugs and that they may be directly administered as aggregates to the cells. Although some studies regarding this field have been found in the literature related to other anticancer drugs with purely organic structures or with nanoparticles,^{40,41} to the best of our knowledge, this analysis has no precedent in the literature with metallodrugs [and, in particular, gold(I) metallodrugs] and is also of great relevance toward ongoing drug design.

For this reason, we have synthesized and studied a series of phosphane–gold(I) 4-ethynylaniline complexes whose biological activity was previously reported by us.¹³ In this work, careful focus has been put on analysis of the behavior of the metallodrugs before they enter the cells, i.e., how the molecules

95 enter the cells and a detailed and complete analysis of their
96 aggregation, in order to retrieve information that should
97 significantly contribute toward the future development and
98 understanding of gold(I) metallodrugs.

99 ■ RESULTS AND DISCUSSION

f1 100 Synthesis of the compounds (Figure 1) was performed
101 following the same procedure previously described by us.¹³
102 As in previously explored work, gold(I) alkynyl complexes are
103 well-known to aggregate, both in the solid state and in solution,
104 giving rise to different supramolecular assem-
105 blies.^{35,35,37,39,42–44} Nevertheless, to the best of our knowledge,
106 the possible correlation between the formation of supra-
107 molecular assemblies and the observed biological activity has
108 not yet been explored and was the goal of the studies presented
109 herein.

f2f3 110 **Aggregation of the Molecules.** Single crystals suitable
111 for X-ray diffraction were obtained from dichloromethane/
112 hexane solutions of **1**, **4**, and **5** (Figures 2 and 3). All
113 complexes present a linear coordination around the gold(I)
114 center, with the P–Au–C angles ranging between 169.2(4)
t1 115 and 177.6(1)° (Table 1). The P–Au and Au–C bond

Table 1. Selected Bond Lengths (Å) and Angles (deg) for **1, **4**, and **5****

compound	distance (Å)	angle (deg)
1a	Au–P: 2.257(7)–2.276(8)	P–Au–C: 173.9(8)–177.4(9)
	Au–C: 1.98(3)–2.05(3)	
	Au···Au: 3.083(2)–3.196(2)	
1b	Au–P: 2.256(3)	P–Au–C: 169.2(4)
	Au–C: 2.02(1)	
	Au···Au: 3.444(1)	
4	Au–P: 2.270(1)/2.277(1)	P–Au–C: 173.7(2)/175.0(2)
	Au–C: 1.995(6)/1.996(6)	
	Au···Au: 7.2276(6)	
5	Au–P: 2.280(1)	P–Au–C: 177.6(1)
	Au–C: 2.010(4)	
	Au···Au: 5.1661(4)	

116 distances are in good agreement with those previously reported
117 for gold(I) complexes with the general structure phosphane–
118 gold alkynyl.^{13,44–47} The three complexes display near-linear
119 geometry of the P–Au–C≡C–C units and N–H···C_{sp} and
120 C–H···π interactions in the 3D crystal packing, both
121 previously reported in the literature,^{13,31,36,48–51} together
122 with auophilic contacts in both **1a** and **1b**.

123 Complex **1** crystallizes in two different solid-state structures,
124 giving colorless and yellow crystals, both of them establishing
125 intermolecular auophilic contacts. The asymmetric unit of the
126 colorless crystals (**1a**) displays two trimers and two molecules
127 of dichloromethane, and the molecules are twisted in
128 antiparallel conformations connected through auophilic
129 intermolecular interactions of 3.083(2)–3.196(2) Å, as
130 observed for other previously reported gold(I) complexes
131 (bearing the same phosphane).^{35,38} On the other hand, the
132 unit cell of the yellow crystals (**1b**) consists of discrete
133 molecules that are connected through auophilic contacts of
134 3.444(1) Å in the 3D crystal packing (Figures 1 and S1 and
135 S2). The asymmetric unit cell of complex **4** contains two
136 molecules in an antiparallel disposition (Figure 3A), while
137 complex **5** crystallizes as a discrete molecule (Figure 3B).

Thus, taking into consideration that the X-ray crystal
structures of complexes **3**, **7**, and **8** were also reported in our
previous work,¹³ the only missing solid-state information is
that corresponding to complexes **2** and **6**. Inclusion of the new
X-crystal data is of great relevance to support the presence of
supramolecular assemblies in all cases in the solid state.
Nevertheless, more studies were needed in order to find out if
these assemblies persisted in solution, as esd expected for these
types of complexes based on previous data.³³ Thus, great effort
was put into this work in order to retrieve some information
about possible aggregation of the molecules in solution. This
will shed some light about the state of the active complexes
being of great relevance for the design of new metallodrugs
with improved activity in their aggregated forms.

The aggregation process starts at the critical aggregation
concentration (c.a.c.), and thus this is a key parameter to be
determined. This concentration may depend on several factors,
such as the interaction between the complex and solvent
(which will depend on the solvent polarity), as well as the
bulkiness of the phosphane and/or nuclearity of the complex.
In this work, the phosphine bulkiness, hydrophobicity, and
nuclearity were modified, while keeping constant all of the
other parameters, including the medium, for the purpose of
drawing better comparisons. Thus, the absorption and
emission spectra at different concentrations were recorded in
water/dimethyl sulfoxide (DMSO) mixtures. The plot of the
absorption or emission maxima versus concentration enabled
determination of the c.a.c. value at the inflection point (Table
2 and Figures S5–S20). It can be observed that all complexes

Table 2. Values of the c.a.c. of Complexes 1–8

compound	c.a.c. (M)	compound	c.a.c. (M)
1	5×10^{-6}	5	5×10^{-6}
2	5×10^{-6}	6	1×10^{-5}
3	1×10^{-5}	7	5×10^{-6}
4	5×10^{-6}	8	5×10^{-6}

tend to aggregate between 5×10^{-6} and 1×10^{-5} M, where an
increase of the baseline is observed because of the dispersion
effect of the aggregates,³⁷ and a new absorption band around
350–400 nm can also be detected in some cases. This new
band may be correlated with the formation of aggregates with
possible auophilic contacts.⁵² A second emission band also
appears at longer wavelengths, around 470 nm, due to the
aggregated species. Thus, the bulkiness of the phosphane does
not seem to be a key parameter in the aggregation process. In
fact, the solubility appeared to be the driving force of this
process, with the lowest c.a.c. values in this medium
determined for the more insoluble tris(naphthyl)- and
diphenylphosphaneacetylene phosphanes.

As expected, emission of the aggregates is affected by the
temperature (Figures S21–S25). It can be seen that the
aggregation process is more favored at higher temperatures,
and it can be assumed that hydrogen-bonding interactions
between the complexes and solvent molecules are broken with
temperature, thereby favoring hydrophobic interactions, as
previously observed for other gold(I) supramolecular assem-
blies.³⁴

The ¹H and ³¹P NMR spectra were performed at different
concentrations in water/DMSO mixtures in order to obtain
additional information regarding which part of the molecule is
more affected during the aggregation process (Figures S26–

192 S36). This mixture of solvents was chosen to best approximate
 193 the biological experimental conditions. The required concen-
 194 trations for NMR experiments are higher than those previously
 195 used in the absorption and emission experiments, and thus
 196 they are all above the c.a.c. The ^1H NMR spectra in DMSO- d_6
 197 were also included for those complexes that present lower
 198 solubility, which hinders identification of the different peaks in
 199 the NMR of the aggregates (see the Supporting Information).
 200 Small peaks can be detected close to the main peaks in all cases
 201 because of the presence of different types of aggregated
 202 species.³⁴ Additionally, it can be observed that the signals
 203 become broader in the presence of deuterated water (D_2O)
 204 because of the more favored resulting supramolecular
 205 assemblies. Particularly relevant is the case of the more
 206 hydrophobic compounds **3** and **6**, where only the peaks of the
 207 aniline can be clearly detected. Nevertheless, the correspond-
 208 ing spectrum in pure DMSO- d_6 indicates correct formation of
 209 the compounds. It can be observed that for those compounds
 210 that contain a more water-soluble phosphane (compounds **1**
 211 and **2** with PTA and DAPTA phosphanes, respectively) a slight
 212 (0.12 ppm) upfield shift in the phosphane protons, together
 213 with the presence of a secondary set of signals related to the
 214 aniline moiety, is recorded in the ^1H NMR spectra. A slight
 215 downfield shift in the ^{31}P NMR spectra (ca. 1.5 ppm) is also
 216 observed. This behavior agrees with the presence of larger
 217 aggregated assemblies at higher concentrations, where both
 218 parts of the molecule (phosphane and aniline group) are
 219 affected. This was previously displayed in the X-ray crystal
 220 structures because the aurophilic contacts (close to the
 221 phosphorus atom) and $\text{N}-\text{H}\cdots\pi$ interactions were involved
 222 in the intermolecular contacts, affecting their NMR chemical
 223 shifts. On the other hand, only the aniline protons are affected
 224 by the concentration in the more hydrophobic compounds
 225 (i.e., compounds **3** and **5–8**) that also display $\text{N}-\text{H}\cdots\pi$
 226 interactions in the X-ray crystal structures. Their lower
 227 solubility in the experimental conditions supports the
 228 formation of more stable aggregates at the lower NMR
 229 concentrations used, which is not affected by the further
 230 increasing concentrations. A particular case is compound **4**,
 231 which contains the triphenylphosphane group, PPh_3 , where
 232 again both parts of the molecule (aniline and phosphane) are
 233 affected by the concentration. The X-ray crystal structure of **4**
 234 (Figure S3) shows the presence of intermolecular contacts
 235 between the phenyl groups ($\text{C}-\text{H}\cdots\pi$), which may be
 236 maintained in solution (in the aggregated form) and can
 237 explain the involvement of phosphane in this process, together
 238 with the $\text{N}-\text{H}\cdots\pi$ interactions involving the aniline.

239 **Correlation between Aggregation and Cell Penetra-**
 240 **tion.** The partition coefficients of the compounds were
 241 retrieved through absorption spectroscopy in water/octanol
 242 mixtures, although the determination of this parameter was
 243 only for complexes that possessed at least partial solubility in
 244 octanol (compounds **3–5** and **8**; Table 3). The observed trend
 245 was $8 > 4 > 3 > 5$. The $\log K_{\text{ow}}$ values are related to the
 246 corresponding hydrophobicity of the complexes, and con-
 247 sequently it is expected that the compounds that possess
 248 extended aromaticity or a rigid phosphane (and therefore
 249 being less soluble in water) might cross the membranes more
 250 easily.

251 The observed aggregation of all of the studied complexes led
 252 to an important question regarding the state of the samples in
 253 the previously studied biological activity. To understand
 254 whether the presence of aggregates plays an important role

Table 3. Partition Coefficients for Compounds 1–8

compound	partition coefficient	$\log K_{\text{ow}}$
1		
2		
3	2.1	0.3
4	4.5	0.7
5	1.2	0.1
6		
7		
8	6.9	0.8

in the previously studied biological activity of the compounds, 255
 several factors were taken into consideration. The first factor 256
 considered was the molecules' behavior in aqueous solutions 257
 and their uptake by the cells, either as monomers or as 258
 aggregates. To shed some light on this issue, absorption 259
 spectroscopy and dynamic light scattering (DLS) experiments 260
 were recorded at different times (points crucial for the 261
 biological assays) and with the same conditions (water 262
 solutions with 0.1% DMSO at 37 °C). In all cases, the 263
 concentrations used were above the c.a.c. values to favor the 264
 formation of aggregates. A decrease in the absorption band is 265
 observed at longer times, together with an increase of the 266
 baseline due to an increase of the formation of aggregates 267
 (Figures S37–S44). Additionally, DLS data revealed that fresh 268
 solutions, considered to be $t = 0$ (recently dissolved 269
 molecules), already possess the molecules in their aggregated 270
 forms (Figures S45–S52), being a clear indication of the fast 271
 kinetic formation of self-assembled structures. Additionally, the 272
 recorded sizes at $t = 3–6$ h are almost constant, which suggests 273
 that the fast formation of aggregates is in equilibrium with 274
 larger or smaller adducts that are finally thermodynamically 275
 stable after this period. Similar experiments carried out in 276
 biological media (phosphate-buffered saline) show that, in this 277
 medium, aggregation is still present, although smaller sizes can 278
 be detected in all cases. The aggregates are also maintained in 279
 the presence of a biologically relevant protein, bovine serum 280
 albumin (BSA), but become smaller (Figures S53–S60). Thus, 281
 these results suggest that complexes are introduced into cells 282
 mostly as aggregates, whose size decreases in the presence of 283
 biological proteins, a relevant finding that, to the best of our 284
 knowledge, has not been extensively studied for metallodrugs 285
 prior to this. Initially, the aggregates of compounds **1**, **2**, **5**, and 286
8 were observed around 150 nm, and those of **3**, **4**, and **6** were 287
 observed at 400–700 nm because of their lower solubility in 288
 this medium. This agrees with an increase of the absorption 289
 spectral baseline for these complexes, being more denoted for 290
3 and **6** with larger aggregates. The time intervals of 0, 1, 3, 291
 and 6 h were chosen because they are most pertinent with 292
 respect to the biological cultures. The observed variations of 293
 the size in the less soluble complexes may be ascribed to an 294
 increase of the self-assembled aggregates with time (in 295
 agreement with the larger broadening recorded in the NMR 296
 spectra), with those being maintained in the suspension 297
 smaller (in the case of **3**) or more homogeneous (sharper 298
 signals) in the case of **6**. A general increase in the aggregates' 299
 size is recorded for the more soluble samples, as expected for 300
 an aggregation process, which is more favored with time. Thus, 301
 the use of more soluble metallodrugs in a biological medium 302
 induces a slower kinetic self-assembly. Interestingly, smaller 303
 sizes were detected for those compounds with shorter $\text{Au}\cdots\text{Au}$ 304
 contacts (according to the X-ray crystal data), suggesting that 305

306 aurophilicity favors the closer contacts between the molecules
 307 with respect to the more extended N–H... π assemblies.
 308 Small-angle X-ray scattering (SAXS) experiments were also
 309 performed in the same solvent and concentration conditions to
 310 verify whether smaller aggregates may be present in the
 311 solutions at the biological temperature conditions. The use of
 312 this technique was relevant to identifying the presence of
 313 aggregated species at lower concentrations, such as those used
 314 for the biological experiments, which were more difficult to
 315 identify by other spectroscopic techniques. The low-resolution
 316 structures were reconstructed ab initio from the scattering
 317 patterns using the DAMMIN program. As can be observed in
 318 Table 4 and Figures S61–S69, small aggregates exist in all

Table 4. Sizes of the Small Aggregates of the Complexes Retrieved through SAXS Experiments under Conditions Analogous to Those Used for Biological Assays

	1	2	3	4	5	6	7	8
size (Å)	269	263	284	189	254	275	389	225

319 cases with sizes around 200–400 Å, which is additional
 320 evidence of the presence of aggregates in solutions of the
 321 studied metallodrugs.

322 Previously we found a correlation between the complex
 323 internalization and cytotoxicity of mononuclear complexes,
 324 with higher intracellular concentrations of gold presenting
 325 lower IC₅₀ values (higher cytotoxicity; Figure S70).¹³ The
 326 same trend was observed for dinuclear complexes. However,
 327 dinuclear complexes with IC₅₀ values similar to those of
 328 mononuclear complexes had higher intracellular percentages of
 329 gold.¹³ This was the case for complexes 7 and 8 (both with
 330 IC₅₀ = 0.3 μ M) with internalizations of 41.7% and 34.4%,
 331 respectively, while complexes 4 (IC₅₀ = 0.1 μ M) and 5 (IC₅₀ =
 332 0.3 μ M) presented 7.2% and 4.0%, respectively, of internalized
 333 gold.¹³ Interestingly, when we compared this data with those
 334 from DLS, complexes 5, 7, and 8 with smaller aggregates
 335 (~200 nm) presented the same IC₅₀ of 0.3 μ M in ovarian
 336 cancer cells.¹³ Larger aggregates (~300 nm) were recorded for
 337 4, with a lower IC₅₀. Hence, the formation of larger aggregates
 338 seems to be a positive point for obtaining better cytotoxicity
 339 values (lower IC₅₀). Because of the sensitivity of the
 340 inductively coupled plasma atomic emission spectrometry
 341 (ICP-AES) technique, analysis of complexes that presented
 342 gold internalization levels higher than 4% (complexes 4, 5, 7,
 343 and 8) was pursued. It must be said that, because of the high
 344 cytotoxicity of the complexes in ovarian cancer cells (low
 345 micromolar range),¹³ biological studies performed at 48 h used
 346 the IC₅₀ concentration of each complex, which is below c.a.c.
 347 Nevertheless, because the ICP-AES experiments were
 348 performed for shorter periods of incubation with the cells
 349 (to understand their internalization), the concentrations used
 350 in these cases were near the c.a.c., allowing better correlation
 351 with the above-described aggregation studies. Moreover, even
 352 in a more complex system (biological media with BSA),
 353 aggregation was still observed (see above). Indeed, the
 354 complexity of the biological media is even higher because it
 355 includes fetal bovine serum, which has different proteins
 356 besides BSA, and as described for other materials, a protein
 357 corona formation cannot be disregarded.⁴⁰

358 It is expected that aggregates of complexes with more than
 359 200 nm might require energy-dependent pathways, such as
 360 endocytosis for internalization.^{41,53} Nevertheless, hydrophobic

complexes might alter this internalization process because they
 361 are more soluble in the membrane lipids. Considering that the
 362 percentage of intracellular gold was evaluated in A2780 cells
 363 incubated with the complexes for 3 h at 4 °C, because the
 364 activity of cellular transporters is temperature-dependent, the
 365 energy-dependent mechanisms would be mostly inhibited at
 366 lower temperatures.^{54,55} Figure 4 shows that, with the
 367




Figure 4. Internalization of complexes 4, 5, 7, and 8 in ovarian cancer cells A2780 after 3 h at 37 °C (dark blue) and 4 °C (light blue) and after 6 h at 37 °C (green). Bars represent the percentage of gold in cells relative to the total amount of gold found in the media and cells for each sample.

exception of complex 5, only a slight decrease of the
 368 internalized gold was observed when the cells were incubated
 369 with the complexes at 4 °C relative to incubation at 37 °C,
 370 suggesting that complexes 4, 7, and 8 might enter A2780 cells
 371 via a passive mechanism. Regarding complex 5, the percentage
 372 of gold inside cells decreased from 3.9% at 37 °C to 0.38% at 4
 373 °C. Although it is tempting to assume that the lower
 374 internalization was due to the inhibition of active transport,
 375 because the uptake of complex 5 might be via an active
 376 transport mechanism, it is important to note that passive
 377 diffusion might also be affected by lower temperature. A
 378 comparison with the absorption, emission, and SAXS data
 379 performed at 37 °C also supports the postulation that in all
 380 cases the aggregates are the internalized species at this
 381 temperature.
 382

In line with the results previously observed for complex 3,¹³
 383 a decrease of the internalization is observed after 6 h in all
 384 complexes, with complex 7 showing the highest deviation,
 385 from 41.7% internalized gold after 3 h to 5.2% internalized
 386 gold after 6 h (Figure 4). This decrease of the internalization of
 387 complexes might be correlated, as in the case of 8, with the
 388 increased size of aggregates over time, as observed by DLS
 389 (Figure S52), or possibly precipitation over time (due to low
 390 water solubility; Table 3).
 391

A dark-field microscopy analysis was performed to under-
 392 stand whether complexes with higher log *K*_{ow} values were
 393 internalized by cells in the aggregated form. The A2780 cells
 394 were exposed for 3 h with the IC₅₀ values of complexes 4 and 8
 395 or with 0.1% (v/v) DMSO as the control sample. The results
 396 showed that cells incubated with complex 4 displayed brighter
 397 spots at the membrane, consistent with a denser material and,
 398 hence, with the presence of complex 4 aggregates (Figure 5).
 399 These results suggest that aggregates of complex 4 interact
 400 with the cell membranes and might be internalized.
 401

To further understand the possible uptake of complexes by
 402 passive mechanisms, particularly for complexes 4, 7, and 8 (5
 403 was also included for comparison), their partition coefficients
 404 were analyzed (Table 3). Interestingly, compounds 4 and 8
 405 show higher partition coefficients, which agrees with their 406




Figure 5. Analysis of the internalization in the aggregated form of complexes 4 and 8. The ovarian cancer cell line A2780 was incubated for 3 h with the IC_{50} values of each complex ($0.1 \mu\text{M}$ for complex 4 and $0.3 \mu\text{M}$ for complex 8) or 0.1% (v/v) DMSO for control purposes and then fixed with formaldehyde 4% (w/v). Images were acquired in an Eclipse Ti-U inverted microscope using a dark-field condenser. Orange arrows point to bright spots consistent with the presence of complex 4 as aggregates.

407 higher affinity for membrane lipids and possible diffusion
408 through them compared to complex 5, as stated above.
409 Altogether, the results suggest that, although the internalization
410 of complex aggregates might not be excluded, as observed in
411 Figure 5, the higher cytotoxicity of 4 might be correlated with
412 its lower size of aggregates recorded by SAXS (Table 4) and its
413 hydrophobicity that can more easily cross cell membranes via
414 passive transport (Table 3).

415 Previously we demonstrated that complex 3 induced
416 intrinsic apoptosis in A2780 cells, possibly because of increased
417 reactive oxygen species production.¹³ To further enlighten the
418 effect of the complexes on A2780 cells, the intracellular
419 distribution within cellular organelles was accessed through
420 cellular fractionation using a detergent-based cell fractionation
421 kit (Cell Signaling Technologies). With this methodology, it is
422 possible to separate the cell content into three fractions: the
423 “cytosolic fraction”, the “mitochondrial fraction” composed of
424 membranes and organelles, and the “nuclear fraction”
425 composed of nuclei and cytoskeletons. The distribution of
426 the complexes throughout the cell fractions was evaluated by
427 ICP-AES. Interestingly, the results suggest that while the
428 original mononuclear complexes are mainly found in the
429 cytosolic fraction, the original dinuclear complexes (7 and 8)
430 are mainly in the later fraction comprised of nuclei and
431 cytoskeletons (Figure 6).




Figure 6. Distribution of complexes 4, 5, 7, and 8 in the ovarian carcinoma cell line A2780. Cells were exposed to $10 \times IC_{50}$ of each complex for 3 h at 37°C . Cells were then fractionated using a cell fractionation kit (Cell Signaling Technologies) into the cytosolic fraction, mitochondrial fraction (composed of membranes and organelles), and nuclear fraction (composed of nuclei and cytoskeletons). The concentration of gold in each fraction was measured by ICP-AES, and the represented percentage of gold in each bar is the gold in each fraction relative to the sum of gold in all fractions.

Because of the high percentage of complexes in the nuclear/
432 cytoskeleton fraction, it was examined whether the complexes
433 interact with actin. With this purpose, A2780 cells were
434 exposed for 0–6 h to the IC_{50} concentration of the
435 mononuclear complex 4 ($0.1 \mu\text{M}$) or to the IC_{50} concentration
436 of the dinuclear complex 8 ($0.3 \mu\text{M}$). Afterward, cells were
437 fixed with formaldehyde, and actin stained with phalloidin
438 (Figures 7 and S71).

439 The results show that both complexes presented some
440 interaction with actin, causing the formation of actin
441 agglomerations, which is consistent with actin disruptions.
442 However, while actin aggregates are present in the cells
443 incubated with complex 4 for 30 min or 1 h, major actin
444 modifications are mainly observed after a 3 h of incubation
445 with complex 8 (Figure 7). A closer look at A2780 cells
446 incubated with both complexes for 3 h revealed that that the
447 actin filaments in cells incubated with complex 8 were more
448 disorganized than those in cells incubated with DMSO
449 (control conditions) or with complex 4. These results might
450 suggest that complex 8 destabilizes the actin cytoskeleton of
451 the cells in a major degree probably because of cooperative
452 effects between the two gold(I) moieties.⁵⁸ The interaction of
453 gold compounds with actin or actin-related proteins in A2780
454 cells was previously described in a proteomic analysis by
455 Messori, Modesti, and co-workers,²³ where they observed a
456 decreased expression of two actin isoforms when cells were
457 incubated with auranofin and Auoxo6. The cytoskeleton
458 modification and/or reorganization was frequently correlated
459 with apoptosis.^{23,59}

460 Nevertheless, aggregation does not seem to affect this
461 process because both complexes 4 and 8 present similar
462 aggregation sizes after 3–6 h. Thus, aggregation seems to be
463 involved in a possible passive mechanism to enter the cells, but
464 the final biological action (once the compounds are already
465 within the cells) is expected to be more susceptible to a
466 cooperative effect related to the nuclearity of the metallodrugs.

CONCLUSIONS

468 Intermolecular interactions in terms of $\text{N}-\text{H}\cdots\pi$ or aurophilic
469 contacts play a key role in the aggregation process of a series of
470 gold(I) metallodrugs, as observed in the X-ray crystal packing,
471 and these aggregates are maintained in solution even at very
472 low concentrations. SAXS experiments were very useful for
473 detecting the presence of small aggregates ($200\text{--}400 \text{ \AA}$) that
474 can give rise to larger structures ($>1000 \text{ \AA}$), as detected by
475 DLS.

476 Correlation between the previously studied biological
477 activity and aggregation motifs determined that the samples
478 are already incorporated within the cells as aggregates that pass
479




Figure 7. Interaction of complexes 4 and 8 with actin. The ovarian cancer cell line A2780 was incubated for 0 h, 30 min, 1 h, 3 h, and 6 h with the IC₅₀ value of each complex (0.1 μ M for complex 4 and 0.3 μ M for complex 8) and then fixed with formaldehyde 4% (w/v). Cells were stained with AlexaFluor 488 phalloidin (Invitrogen), and images were acquired on an Eclipse Ti-U inverted microscope with a green filter cube (excitation filter range at 465–495 nm and emission filter range at 515–555 nm). Orange arrows point to actin agglomerations in cells.

480 through the cellular membranes, possibly through a passive
481 diffusion mechanism. Nevertheless, once inside the cells, their
482 biological activity and subcellular localization seem to be more
483 correlated with the original nuclearity of the complexes. These
484 preliminary studies indicate that a wider array of complexes
485 should be analyzed in order to obtain additional evidence that
486 the nuclearity may favor the targeting of complexes to specific
487 biological subcellular compartments.

488 To the best of our knowledge, a study of the mechanism of
489 entering the cells in these types of complexes has no precedent
490 in the literature and is of great relevance to better understand
491 their behavior and toward increased efficacy in the future drug
492 design of metallodrugs.

493 ■ EXPERIMENTAL SECTION

494 **General Procedures.** All manipulations were performed under
495 prepurified N₂ using standard Schlenk techniques. All solvents were
496 distilled from the appropriate drying agents. Literature methods were
497 used to prepare 4-ethynylaniline gold(I) complexes containing
498 monophosphane [1,3,5-triaza-7-phosphaadamantane (pta; 1), 3,7-
499 diacetyl-1,3,7-triaza-5-phosphabicyclo[3.3.1]nonane (2), and PR₃,
500 with R = naphthyl (3), phenyl (4), and ethyl (5)] and diphosphane
501 [bis(diphenylphosphino)acetylene (dppa; 6), 1,2-bis-
502 (diphenylphosphino)ethane (dppe; 7), and 1,3-bis-
503 (diphenylphosphino)propane (dppp; 8)].¹³

504 **Physical Measurements.** IR spectra were recorded on a Nicolet
505 FT-IR 520 spectrophotometer. ¹H NMR [δ (TMS) = 0.0 ppm] and
506 ³¹P{¹H} NMR [δ (85% H₃PO₄) = 0.0 ppm] spectra were obtained on
507 Varian Mercury 400 and Bruker 400 spectrometers (Universitat de
508 Barcelona). Electrospray ionization mass spectrometry (positive-ion
509 mode) spectra were recorded on a Fisons VG Quatro spectrometer
510 (Universitat de Barcelona). Absorption spectra were recorded on a
511 Varian Cary 100 UV–spectrophotometer and emission spectra on
512 a Horiba-Jobin-Yvon SPEX Nanolog spectrofluorimeter (Universitat
513 de Barcelona). DLS spectra were obtained on a Zetasizer Nano S of
514 Malvern (Parc Científic de Barcelona). The samples were measured in
515 quartz cuvettes. SAXS was performed on the NCD-SWEET beamline
516 at the ALBA Synchrotron at 12.4 keV, and the sample/detector
517 distance was 6.2 m to cover the range of momentum transfer of 0.028
518 nm⁻¹ < q < 2.56 nm⁻¹. The data were collected on a Pilatus3S 1 M

519 detector with a pixel size of 172.0 \times 172.0 μ m². The exposure time
520 was 30 s. The q -axis calibration was obtained by measuring silver
521 behenate.⁶⁰ The program *pyFAI* was used to integrate the 2D SAXS
522 data into 1D data.⁶¹ The data were then subtracted by the background
523 using *PRIMUS* software.⁶² The maximum particle dimension D_{\max}
524 and the pair distance distribution $P(r)$ were determined with *GNOM*.⁶²
525 The low-resolution structure of the aggregates was reconstructed ab
526 initio from the initial portions of the scattering patterns using the
527 *DAMMIN* program.⁶³

528 **X-ray Crystal Structure Determination.** The crystal data and
529 experimental details for the data collection of 1a (CCDC 2070637),
530 1b (CCDC 2070638), 4 (CCDC 2070639), and 5 (CCDC 2070640)
531 are given in Table S1. The single-crystal data for 1a, 1b, and 4 were
532 collected using a Bruker-Nonius Kappa CCD diffractometer with an
533 APEX-II detector with graphite-monochromatized Mo K α (λ =
534 0.71073 Å) radiation. Data collection and reduction were performed
535 using the programs *COLLECT*⁶⁴ and *HKL DENZO AND*
536 *SCALEPACK*,⁶⁵ respectively, and the intensities were corrected for
537 absorption using *SADABS*.⁶⁶ Single-crystal X-ray data for 5 were
538 measured using a Rigaku SuperNova dual-source Oxford diffrac-
539 tometer equipped with an Atlas detector using mirror-monochromat-
540 ized Cu K α (λ = 1.54184 Å) radiation. Data collection and
541 reduction were performed using the program *CrysAlisPro*.⁶⁷ The
542 structures were solved with intrinsic phasing (*SHELXT*).⁶⁸ Non-
543 hydrogen atoms were assigned anisotropic displacement parameters
544 unless stated otherwise. Hydrogen atoms were placed in idealized
545 positions and included as riding. The isotropic displacement
546 parameters for all hydrogen atoms were constrained to multiples of
547 $U_{\text{iso}}(\text{H}) = 1.2U_{\text{eq}}(\text{parent atom})$.

548 **Aggregation Studies.** The c.a.c. was obtained by recording the
549 absorption, excitation, and emission spectra at different concen-
550 trations (5×10^{-5} – 10^{-6} M) in a mixture of DMSO and water (50:50
551 in the case of 1–5 and 8 or 60:40 in the case of 6 and 7).
552

553 NMR studies at different concentrations (5.5×10^{-3} – 2.4×10^{-4})
554 were carried out by dissolving the corresponding quantity of
555 compound in a DMSO-*d*₆/D₂O mixture (50:50 in the case of 1–5
556 and 8 or 60:40 in the case of 6 and 7).

557 The samples for SAXS were prepared 1 week before in order to
558 favor the aggregation processes at different concentrations (10^{-4} – $5 \times$
559 10^{-6} M) in water for 1 and 2 and in water/tetrahydrofuran mixtures
560 (50:50) for 3–8.

561 Time-dependent studies of 10^{-5} M water solutions containing 0.1%
562 DMSO were followed by absorption spectroscopy and DLS at
563 different times (0, 1, 3, and 6 h) at 37 °C.

564 **Partition Coefficient.** The partition coefficient was calculated
565 following literature methods.⁶⁹

566 **Biological Assays. Cell Culture and Cell Culture Maintenance.**
567 Human ovarian carcinoma, A2780, purchased from ATCC
568 (Manassas, VA) was grown and maintained in an RPMI 1640
569 medium (Gibco, ThermoFisher Scientific, Waltham, MA), supple-
570 mented with 10% (v/v) fetal bovine serum (Gibco, ThermoFisher
571 Scientific), 1% (v/v) nonessential amino acids (MEM; Gibco,
572 ThermoFisher Scientific), and a mixture of 100 U/mL penicillin
573 and 100 µg/mL streptomycin (Gibco, ThermoFisher Scientific) at 37
574 °C and 5% (v/v) CO₂ in a humidified atmosphere.⁷⁰

575 **Cellular Uptake of Complexes 4, 5, 7, and 8 by A2780 Cells.** To
576 evaluate the internalization of the complexes, 2×10^6 A2780 cells
577 were seeded in a 25 cm² T-flask and allowed to adhere for 24 h.
578 Afterward, the media were replaced by fresh media supplemented
579 with 10 times the respective IC₅₀ value of each complex and incubated
580 for 3 h at 37 and 4 °C or for 6 h at 37 °C. The supernatant was
581 transferred to a clean tube, and the cells were washed with PBS that
582 was added to the supernatant-containing tube. The cells were then
583 detached with TrypLE Express (ThermoFisher Scientific) and
584 pelleted with 500g centrifugation for 5 min. The supernatant was
585 transferred to the supernatant-containing tube, and both the cells and
586 supernatant samples were incubated with aqua regia overnight. The
587 amount of gold in each sample was quantified with ICP-AES. The
588 percentage of intracellular gold was calculated by dividing the gold
589 concentration in the cells by the sum of the gold concentrations in the
590 respective supernatants and cell pellets.¹³

591 **Distribution of Complexes 4, 5, 7, and 8 in Cellular Fractions.**
592 A2780 cells were seeded in 25 cm² T-flasks in a density of 6×10^5
593 cells/mL. After 24 h, the cells were exposed to fresh media
594 supplemented with $10 \times$ IC₅₀ of each complex and incubated for 3
595 h at 37 °C and 5% (v/v) CO₂ in a humidified atmosphere. Afterward,
596 the cells were collected with a cell scraper in PBS, pelleted with 500g
597 centrifugation for 5 min, and fractionated with a Cell Fractionation
598 Kit (Cell Signaling Technologies, Danvers, MA) according to the
599 manufacturer's instructions. With this protocol, three fractions were
600 obtained: the cytoplasmic fraction, mitochondrial fraction, composed
601 of membranes and organelles, and nuclear fraction. After incubation
602 of each obtained fraction with aqua regia, the amount of gold was
603 quantified with ICP-AES. The percentage of gold in each fraction was
604 calculated by dividing the gold concentration in the specific fraction
605 with the sum of the gold concentrations in the respective cytoplasmic,
606 mitochondrial, and nuclear fractions.

607 **Interaction of Complexes 4 and 8 with Actin.** A2780 cells were
608 seeded in a 24-well plate in a cell density of 37500 cells/well. After 24
609 h, the media were replaced by the IC₅₀ value of complex 4 (0.1 µM),
610 the IC₅₀ value of complex 8 (0.3 µM), or 0.1% (v/v) DMSO, the
611 vehicle solvent of the complexes. After 0 h, 30 min, 1 h, 3 h, or 6 h of
612 incubation, the cells were fixed with 4% (w/v) formaldehyde (Sigma-
613 Aldrich, Merck, Kenilworth, NJ) for 15 min and washed three times
614 with PBS. The cell membrane was then disrupted by a 5 min
615 incubation with 0.1% (v/v) Triton (Sigma-Aldrich, Merck) and
616 washed three times with PBS, and the cells were incubated for 30 min
617 with 1% (w/v) bovine serum albumin (BSA; NZYtech, Lisbon,
618 Portugal) and 20 min with AlexaFluor 488 phalloidin (Invitrogen,
619 ThermoFisher Scientific), as previously described.⁷¹ After washing
620 three times with PBS, the cells were visualized with an Eclipse Ti-U
621 inverted microscope with a green filter cube (an excitation filter range
622 at 465–495 nm and an emission filter range at 515–555 nm), and
623 images were acquired with the respective microscope software. Three
624 different images with around 20 cells were acquired per sample with a
625 40× objective, or five different images with around five cells were
626 acquired with a 100× objective.

627 **Dark-Field Analysis.** A2780 cells were seeded in a 24-well plate in a
628 cell density of 37500 cells/well. After 24 h, the media were replaced
629 by the IC₅₀ value of complex 4 (0.1 µM), the IC₅₀ value of complex 8
630 (0.3 µM), or 0.1% (v/v) DMSO, the vehicle solvent of the complexes.

After 3 h of incubation, the cells were fixed with 4% (w/v) 631
formaldehyde (Sigma-Aldrich, Merck) for 15 min and washed three 632
times with PBS. The cells were visualized with an Eclipse Ti-U 633
inverted microscope using a dark-field condenser and a 100× 634
objective. Five different images with around five cells were acquired 635
per sample. 636

■ ASSOCIATED CONTENT

Supporting Information

The Supporting Information is available free of charge at 639
<https://pubs.acs.org/doi/10.1021/acs.inorgchem.1c02359>. 640

X-ray packing of the molecules, absorption and emission 641
spectra of the compounds at different concentrations, 642
emission spectra of the compounds at different temper- 643
atures, ¹H and ³¹P NMR spectra of the compounds at 644
different concentrations in a mixture of D₂O/DMSO-*d*₆, 645
absorption spectra of the compounds at different times, 646
DLS spectra of the compounds at different times, SAXS 647
data of the compounds at diluted conditions, plot 648
representing the percentage of gold internalized versus 649
IC₅₀ values against the A2780 cell line, interaction of 650
complexes 4 and 8 with actin, crystal data and structures 651
for 1a, 1b, 4, and 5, and internalization data of 652
complexes 4, 5, 7, and 8 in ovarian cancer cells A2780 653
after 3 h at 37 and 4 °C and after 6 h at 37 °C (PDF) 654

Accession Codes

CCDC 2070637–2070640 contain the supplementary crys- 655
tallographic data for this paper. These data can be obtained 656
free of charge via www.ccdc.cam.ac.uk/data_request/cif, or by 657
emailing data_request@ccdc.cam.ac.uk, or by contacting The 658
Cambridge Crystallographic Data Centre, 12 Union Road, 659
Cambridge CB2 1EZ, UK; fax: +44 1223 336033. 660

■ AUTHOR INFORMATION

Corresponding Authors

Alexandra R. Fernandes – UCIBIO—Applied Molecular 664
Biosciences Unit, Department of Life Sciences and Associate 665
Laboratory i4HB, Institute for Health and Bioeconomy, 666
NOVA School of Science and Technology, NOVA University 667
Lisbon, 2819-516 Caparica, Portugal; orcid.org/0000-0003-2054-4438; Email: ma.fernandes@fct.unl.pt 668

Laura Rodríguez – Departament de Química Inorgànica i 670
Orgànica, Secció de Química Inorgànica, Universitat de 671
Barcelona, E-08028 Barcelona, Spain; Institut de 672
Nanociència i Nanotecnologia (IN²UB), Universitat de 673
Barcelona, 08028 Barcelona, Spain; orcid.org/0000-0003-1289-1587; Email: laura.rodriguez@qi.ub.es 674

Authors

Andrea Pinto – Departament de Química Inorgànica i 677
Orgànica, Secció de Química Inorgànica, Universitat de 678
Barcelona, E-08028 Barcelona, Spain; Institut de 679
Nanociència i Nanotecnologia (IN²UB), Universitat de 680
Barcelona, 08028 Barcelona, Spain 681

Catarina Roma-Rodrigues – UCIBIO—Applied Molecular 682
Biosciences Unit, Department of Life Sciences and Associate 683
Laboratory i4HB, Institute for Health and Bioeconomy, 684
NOVA School of Science and Technology, NOVA University 685
Lisbon, 2819-516 Caparica, Portugal 686

Jas S. Ward – Department of Chemistry, University of 687
Jyväskylä, 40014 Jyväskylä, Finland; orcid.org/0000-0001-9089-9643 688

690 **Rakesh Puttreddy** – Faculty of Engineering and Natural
691 Sciences, Tampere University, FI-33101 Tampere, Finland;
692 orcid.org/0000-0002-2221-526X

693 **Kari Rissanen** – Department of Chemistry, University of
694 Jyväskylä, 40014 Jyväskylä, Finland; orcid.org/0000-0002-7282-8419

695 **Pedro V. Baptista** – UCIBIO—Applied Molecular Biosciences
696 Unit, Department of Life Sciences and Associate Laboratory
697 i4HB, Institute for Health and Bioeconomy, NOVA School of
698 Science and Technology, NOVA University Lisbon, 2819-516
699 Caparica, Portugal; orcid.org/0000-0001-5255-7095

700 **João Carlos Lima** – LAQV-REQUIMTE, Departamento de
701 Química, CQFB, Universidade Nova de Lisboa, 2825-152
702 Monte de Caparica, Portugal; orcid.org/0000-0003-0528-1967

703 Complete contact information is available at:
704 <https://pubs.acs.org/10.1021/acs.inorgchem.1c02359>

707 Author Contributions

708 †These authors made equal contributions.

709 Notes

710 The authors declare no competing financial interest.

711 ACKNOWLEDGMENTS

712 The authors are grateful to the Spanish Ministerio de Ciencia,
713 Innovación y Universidades (Project PID2019-104121GB-
714 I00). This work was supported by the Associate Laboratory for
715 Green Chemistry, LAQV, which is financed by national funds
716 from FCT/MCTES (Grants UIDB/50006/2020 and UIDP/
717 50006/2020). This work was also financed by national funds
718 from Fundação para a Ciência e a Tecnologia, I.P., in the scope
719 of Projects UIDP/04378/2020 and UIDB/04378/2020 of the
720 Research Unit on Applied Molecular Biosciences, UCIBIO,
721 and Project LA/P/0140/2020 of the Associate Laboratory
722 Institute for Health and Bioeconomy, i4HB. SAXS experiments
723 were performed at the NCD-BL11 beamline of the ALBA
724 Synchrotron Light Facility in collaboration with the ALBA
725 staff. The authors also acknowledge COST Actions CA1740—
726 Nano4clinics and CA18202—NECTAR. The Finnish Cultural
727 Foundation (Grant 00201148 to J.S.W.) is also acknowledged
728 for their support.

729 REFERENCES

730 (1) Rubbiani, R.; Wahrig, B.; Ott, I. Historical and Biochemical
731 Aspects of a Seventeenth Century Gold-Based Aurum Vitae Recipe.
732 *J. Biol. Inorg. Chem.* **2014**, *19* (6), 961–965.
733 (2) [João Carlos Lima](https://orcid.org/0000-0003-0528-1967), J.; Rodriguez, L. Phosphine-Gold(I) Compounds
734 as Anticancer Agents: General Description and Mechanisms of
735 Action. *Anti-Cancer Agents Med. Chem.* **2011**, *11* (10), 921–928.
736 (3) (a) Kupiec, M.; Ziolkowski, R.; Massai, L.; Messori, L.; Pawlak,
737 K. The Electrochemical Profiles of Auranofin and Aubipyc, Two
738 Representative Medicinal Gold Compounds: A Comparative Study. *J.*
739 *Inorg. Biochem.* **2019**, *198*, 110714. (b) Jakob, C. H. G.; Muñoz, A.
740 W.; Schlagintweit, J. F.; Weiß, V.; Reich, R. M.; Sieber, S. A.; Correia,
741 J. D. G.; Kühn, F. E. Anticancer and antibacterial properties of
742 trinuclear Cu(I), Ag(I) and Au(I) macrocyclic NHC/urea complexes.
743 *J. Organomet. Chem.* **2021**, *932*, 121643.
744 (4) (a) Palermo, G.; Spinello, A.; Saha, A.; Magistrato, A. Frontiers
745 of Metal-Coordinating Drug Design. *Expert Opin. Drug Discovery*
746 **2021**, *16* (5), 497–511. (b) Zhang, J.-J.; Abu el Maaty, M. A.;
747 Hoffmeister, H.; Schmidt, C.; Muenzner, J. K.; Schobert, R.; Wölfl, S.;
748 Ott, I. A Multitarget Gold(I) Complex Induces Cytotoxicity Related
749 to Aneuploidy in HCT-116 Colorectal Carcinoma Cells. *Angew.*
750 *Chem., Int. Ed.* **2020**, *59*, 16795–16800.

(5) (a) Tolbatov, I.; Coletti, C.; Marrone, A.; Re, N. Insight into the
751 Substitution Mechanism of Antitumor Au(I) N-Heterocyclic Carbene
752 Complexes by Cysteine and Selenocysteine. *Inorg. Chem.* **2020**, *59*
753 (5), 3312–3320. (b) Bian, M.; Sun, Y.; Liu, Y.; Xu, Z.; Fan, R.; Liu,
754 Z.; Liu, W. A Gold(I) Complex Containing an Oleanolic Acid
755 Derivative as a Potential Anti-Ovarian-Cancer Agent by Inhibiting
756 TrxR and Activating ROS-Mediated ERS. *Chem. - Eur. J.* **2020**, *26*,
757 7092–7108.
758 (6) (a) Mármol, I.; Montanel-Perez, S.; Royo, J. C.; Gimeno, M. C.;
759 Villacampa, M. D.; Rodríguez-Yoldi, M. J.; Cerrada, E. Gold(I) and
760 Silver(I) Complexes with 2-Anilinopyridine-Based Heterocycles as
761 Multitarget Drugs against Colon Cancer. *Inorg. Chem.* **2020**, *59* (23),
762 17732–17745. (b) Morgen, M.; Fabrowski, P.; Amtmann, E.; Gunkel,
763 N.; Miller, A. K. Inclusion Complexes of Gold(I)-Dithiocarbamates
764 with β -Cyclodextrin: A Journey from Drug Repurposing towards Drug
765 Discovery. *Chem. - Eur. J.* **2021**, *27*, 12156–12165.
766 (7) (a) Silva, M. J. S. A.; Gois, P. M. P.; Gasser, G. Unveiling the
767 Potential of Transition Metal Complexes for Medicine: Translational
768 in Situ Activation of Metal-Based Drugs from Bench to in Vivo
769 Applications. *ChemBioChem* **2021**, *22* (10), 1740–1742. (b) Bayr-
770 akdar, T. A. C. A.; Scattolin, T.; Ma, X.; Nolan, S. P. Dinuclear gold(I)
771 complexes: from bonding to applications. *Chem. Soc. Rev.* **2020**, *49*,
772 7044–7100.
773 (8) Redrado, M.; Fernández-Moreira, V.; Gimeno, M. C.
774 Theranostics Through the Synergistic Cooperation of Heterometallic
775 Complexes. *ChemMedChem* **2021**, *16* (6), 932–941.
776 (9) Johnson, A.; Marzo, I.; Gimeno, M. C. Heterobimetallic
777 Propargyl Gold Complexes with π -Bound Copper or Silver with
778 Enhanced Anticancer Activity. *Dalton Trans.* **2020**, *49* (33), 11736–
779 11742.
780 (10) Odachowski, M.; Marschner, C.; Blom, B. A Review on 1,1-
781 Bis(Diphenylphosphino)Methane Bridged Homo- and Heterobime-
782 tallic Complexes for Anticancer Applications: Synthesis, Structure,
783 and Cytotoxicity. *Eur. J. Med. Chem.* **2020**, *204*, 112613.
784 (11) Marzo, T.; Messori, L. A Role for Metal-Based Drugs in
785 Fighting COVID-19 Infection? The Case of Auranofin. *ACS Med.*
786 *Chem. Lett.* **2020**, *11* (6), 1067–1068.
787 (12) Gil-Moles, M.; Basu, U.; Büssing, R.; Hoffmeister, H.; Türck,
788 S.; Varchmin, A.; Ott, I. Gold Metallodrugs to Target Coronavirus
789 Proteins: Inhibitory Effects on the Spike-ACE2 Interaction and on
790 PLpro Protease Activity by Auranofin and Gold Organometallics.
791 *Chem. - Eur. J.* **2020**, *26* (66), 15140–15144.
792 (13) Svahn, N.; Moro, A. J.; Roma-Rodrigues, C.; Puttreddy, R.;
793 Rissanen, K.; Baptista, P. V.; Fernandes, A. R.; Lima, J. C.; Rodríguez,
794 L. The Important Role of the Nuclearity, Rigidity, and Solubility of
795 Phosphane Ligands in the Biological Activity of Gold(I) Complexes.
796 *Chem. - Eur. J.* **2018**, *24* (55), 14654–14667.
797 (14) Meyer, A.; Bagowski, C. P.; Kokoschka, M.; Stefanopoulou, M.;
798 Alborzinia, H.; Can, S.; Vleck, D. H.; Sheldrick, W. S.; Wölfl, S.;
799 Ott, I. On the Biological Properties of Alkynyl Phosphine Gold(I)
800 Complexes. *Angew. Chem., Int. Ed.* **2012**, *51* (35), 8895–8899.
801 (15) Mármol, I.; Castellnou, P.; Alvarez, R.; Gimeno, M. C.;
802 Rodríguez-Yoldi, M. J.; Cerrada, E. Alkynyl Gold(I) Complexes
803 Derived from 3-Hydroxyflavones as Multi-Targeted Drugs against
804 Colon Cancer. *Eur. J. Med. Chem.* **2019**, *183*, 111661.
805 (16) Andermark, V.; Göke, K.; Kokoschka, M.; Abu el Maaty, M. A.;
806 Lum, C. T.; Zou, T.; Sun, R. W.-Y.; Aguiló, E.; Oehninger, L.;
807 Rodríguez, L.; Bunjes, H.; Wölfl, S.; Che, C.-M.; Ott, I. Alkynyl
808 Gold(I) Phosphane Complexes: Evaluation of Structure–Activity-
809 Relationships for the Phosphane Ligands, Effects on Key Signaling
810 Proteins and Preliminary in-Vivo Studies with a Nanoformulated
811 Complex. *J. Inorg. Biochem.* **2016**, *160*, 140–148.
812 (17) Chui, C.-H.; Wong, R. S.-M.; Gambari, R.; Cheng, G. Y.-M.;
813 Yuen, M. C.-W.; Chan, K.-W.; Tong, S.-W.; Lau, F.-Y.; Lai, P. B.-S.;
814 Lam, K.-H.; Ho, C.-L.; Kan, C.-W.; Leung, K. S.-Y.; Wong, W.-Y.
815 Antitumor Activity of Diethynylfluorene Derivatives of Gold(I).
816 *Bioorg. Med. Chem.* **2009**, *17* (23), 7872–7877.
817 (18) Meyer, A.; Gutiérrez, A.; Ott, I.; Rodríguez, L. Phosphine-
818 Bridged Dinuclear Gold(I) Alkynyl Complexes: Thioredoxin 819

- 820 Reductase Inhibition and Cytotoxicity. *Inorg. Chim. Acta* **2013**, *398*, 821 72–76.
- 822 (19) Gavara, R.; Aguiló, E.; Schur, J.; Llorca, J.; Ott, I.; Rodríguez, L. 823 Study of the Effect of the Chromophore and Nuclearity on the 824 Aggregation and Potential Biological Activity of Gold(I) Alkynyl 825 Complexes. *Inorg. Chim. Acta* **2016**, *446*, 189–197.
- 826 (20) Dalmases, M.; Pinto, A.; Lippmann, P.; Ott, I.; Rodríguez, L.; 827 Figuerola, A. Preparation and Antitumoral Activity of Au-Based 828 Inorganic-Organometallic Nanocomposites. *Front. Chem.* **2019**, *7* 829 (FEB), 1–10.
- 830 (21) Casini, A. Exploring the Mechanisms of Metalbased 831 Pharmacological Agents via an Integrated Approach. *J. Inorg. Biochem.* 832 **2012**, *109*, 97–106.
- 833 (22) Wang, Y.; Li, H.; Sun, H. Metalloproteomics for Unveiling the 834 Mechanism of Action of Metallo-drugs. *Inorg. Chem.* **2019**, *58* (20), 835 13673–13685.
- 836 (23) Guidi, F.; Landini, I.; Puglia, M.; Magherini, F.; Gabbiani, C.; 837 Cinelli, M. A.; Nobili, S.; Fiaschi, T.; Bini, L.; Mini, E.; Messori, L.; 838 Modesti, A. Proteomic Analysis of Ovarian Cancer Cell Responses to 839 Cytotoxic Gold Compounds. *Metallomics* **2012**, *4* (3), 307.
- 840 (24) Rackham, O.; Nichols, S. J.; Leedman, P. J.; Berners-Price, S. J.; 841 Filipovska, A. A Gold(I) Phosphine Complex Selectively Induces 842 Apoptosis in Breast Cancer Cells: Implications for Anticancer 843 Therapeutics Targeted to Mitochondria. *Biochem. Pharmacol.* **2007**, 844 *74* (7), 992–1002.
- 845 (25) Meyer, A.; Grotefend, S.; Gross, A.; Wätzig, H.; Ott, I. Total 846 Reflection X-Ray Fluorescence Spectrometry as a Tool for the 847 Quantification of Gold and Platinum Metallo-drugs: Determination of 848 Recovery Rates and Precision in the Ppb Concentration Range. *J.* 849 *Pharm. Biomed. Anal.* **2012**, *70*, 713–717.
- 850 (26) Loreto, D.; Ferraro, G.; Merlino, A. Protein-Metallo-drugs 851 Interactions: Effects on the Overall Protein Structure and Character- 852 ization of Au, Ru and Pt Binding Sites. *Int. J. Biol. Macromol.* **2020**, 853 *163*, 970–976.
- 854 (27) de Almeida, A.; Mósca, A. F.; Wragg, D.; Wenzel, M.; 855 Kavanagh, P.; Barone, G.; Leoni, S.; Soveral, G.; Casini, A. The 856 Mechanism of Aquaporin Inhibition by Gold Compounds Elucidated 857 by Biophysical and Computational Methods. *Chem. Commun.* **2017**, 858 *53* (27), 3830–3833.
- 859 (28) Jacques, A.; Lebrun, C.; Casini, A.; Kieffer, I.; Proux, O.; 860 Latour, J.-M.; Sénèque, O. Reactivity of Cys 4 Zinc Finger Domains 861 with Gold(III) Complexes: Insights into the Formation of “Gold 862 Fingers”. *Inorg. Chem.* **2015**, *54* (8), 4104–4113.
- 863 (29) Meier-Menches, S. M.; Aikman, B.; Döllerer, D.; Klooster, W. 864 T.; Coles, S. J.; Santi, N.; Luk, L.; Casini, A.; Bonsignore, R. 865 Comparative Biological Evaluation and G-Quadruplex Interaction 866 Studies of Two New Families of Organometallic Gold(I) Complexes 867 Featuring N-Heterocyclic Carbene and Alkynyl Ligands. *J. Inorg.* 868 *Biochem.* **2020**, *202*, 110844.
- 869 (30) Wragg, D.; de Almeida, A.; Bonsignore, R.; Kühn, F. E.; Leoni, 870 S.; Casini, A. On the Mechanism of Gold/NHC Compounds Binding 871 to DNA G-Quadruplexes: Combined Metadynamics and Biophysical 872 Methods. *Angew. Chem., Int. Ed.* **2018**, *57* (44), 14524–14528.
- 873 (31) Pujadas, M.; Rodríguez, L. Luminescent Phosphine Gold(I) 874 Alkynyl Complexes. Highlights from 2010 to 2018. *Coord. Chem. Rev.* 875 **2020**, *408*, 213179.
- 876 (32) Raubenheimer, H. G.; Schmidbaur, H. Gold Chemistry Guided 877 by the Isolobality Concept. *Organometallics* **2012**, *31* (7), 2507–2522.
- 878 (33) Aguiló, E.; Moro, A. J.; Gavara, R.; Alfonso, I.; Pérez, Y.; 879 Zaccaria, F.; Guerra, C. F.; Malfois, M.; Baucells, C.; Ferrer, M.; Lima, 880 J. C.; Rodríguez, L. Reversible Self-Assembly of Water-Soluble 881 Gold(I) Complexes. *Inorg. Chem.* **2018**, *57* (3), 1017–1028.
- 882 (34) Gavara, R.; Aguiló, E.; Fonseca Guerra, C.; Rodríguez, L.; Lima, 883 J. C. Thermodynamic Aspects of Auophilic Hydrogelators. *Inorg.* 884 *Chem.* **2015**, *54* (11), 5195–5203.
- 885 (35) Moro, A. J.; Rome, B.; Aguiló, E.; Arcau, J.; Puttreddy, R.; 886 Rissanen, K.; Lima, J. C.; Rodríguez, L. A Coumarin Based Gold(I)- 887 Alkynyl Complex: A New Class of Supramolecular Hydrogelators. 888 *Org. Biomol. Chem.* **2015**, *13* (7), 2026–2033.
- (36) Lima, J. C.; Rodríguez, L. Supramolecular Gold Metal- 889 logelators: The Key Role of Metallophilic Interactions. *Inorganics* 890 **2015**, *3* (1), 1–18.
- (37) Pinto, A.; Svahn, N.; Lima, J. C.; Rodríguez, L. Aggregation 892 Induced Emission of Gold(I) Complexes in Water or Water Mixtures. 893 *Dalton Trans.* **2017**, *46* (34), 11125–11139. 894
- (38) Gavara, R.; Pinto, A.; Donamaria, R.; Olmos, M. E.; López de 895 Luzuriaga, J. M.; Rodríguez, L. Polarized Supramolecular Aggregates 896 Based on Luminescent Perhalogenated Gold Derivatives. *Inorg. Chem.* 897 **2017**, *56* (19), 11946–11955. 898
- (39) Pinto, A.; Hernández, G.; Gavara, R.; Aguiló, E.; Moro, A. J.; 899 Aullón, G.; Malfois, M.; Lima, J. C.; Rodríguez, L. Supramolecular 900 Tripodal Au(I) Assemblies in Water. Interactions with a Pyrene 901 Fluorescent Probe. *New J. Chem.* **2019**, *43* (21), 8279–8289. 902
- (40) Caracciolo, G.; Callipo, L.; De Sanctis, S. C.; Cavaliere, C.; 903 Pozzi, D.; Laganà, A. Surface adsorption of protein corona controls 904 the cell internalization mechanism of DC-Chol-DOPE/DNA 905 lipoplexes in serum. *Biochim. Biophys. Acta, Biomembr.* **2010**, *1798*, 906 536–543. 907
- (41) Prabha, S.; Arya, G.; Chandra, R.; Ahmed, B.; Nimesh, S. Effect 908 of Size on Biological Properties of Nanoparticles Employed in Gene 909 Delivery. *Artif. Cells, Nanomed., Biotechnol.* **2016**, *44* (1), 83–91. 910
- (42) Gavara, R.; Llorca, J.; Lima, J. C.; Rodríguez, L. A Luminescent 911 Hydrogel Based on a New Au(I) Complex. *Chem. Commun.* **2013**, *49* 912 (1), 72–74. 913
- (43) Aguiló, E.; Gavara, R.; Baucells, C.; Guitart, M.; Lima, J. C.; 914 Llorca, J.; Rodríguez, L. Tuning Supramolecular Auophilic 915 Structures: The Effect of Counterion, Positive Charge and Solvent. 916 *Dalton Trans.* **2016**, *45* (17), 7328–7339. 917
- (44) Svahn, N.; Sanz, I.; Rissanen, K.; Rodríguez, L. Supramolecular 918 Assemblies and Photophysical Properties of Ionic Homo- and 919 Heteronuclear Metallophilic Complexes. *J. Organomet. Chem.* **2019**, 920 *897*, 170–177. 921
- (45) Aquino, A.; Caparrós, F. J.; Aullón, G.; Ward, J. S.; Rissanen, 922 K.; Jung, Y.; Choi, H.; Lima, J. C.; Rodríguez, L. Effect of Gold(I) on 923 the Room-Temperature Phosphorescence of Ethynylphenanthrene. 924 *Chem. - Eur. J.* **2021**, *27* (5), 1810–1820. 925
- (46) de Aquino, A.; Caparrós, F. J.; Truong, K.; Rissanen, K.; Ferrer, 926 M.; Jung, Y.; Choi, H.; Lima, J. C.; Rodríguez, L. Gold(I)-Doped 927 Films: New Routes for Efficient Room Temperature Phosphorescent 928 Materials. *Dalton Trans.* **2021**, *50*, 3806. 929
- (47) Ferrer, M.; Giménez, L.; Gutiérrez, A.; Lima, J. C.; Martínez, 930 M.; Rodríguez, L.; Martín, A.; Puttreddy, R.; Rissanen, K. Polypyridyl- 931 Functionalized Alkynyl Gold(I) Metallaligands Supported by Tri- 932 and Tetradentate Phosphanes. *Dalton Trans.* **2017**, *46* (40), 13920– 933 13934. 934
- (48) Casini, A.; Lima, J.; Rodríguez, L. Applications of Gold(i) Alkynyl 935 Systems: A Growing Field to Explore. *Chem. Soc. Rev.* **2011**, *40* (11), 936 5442. 937
- (49) Schmidbaur, H.; Schier, A. Auophilic Interactions as a Subject 938 of Current Research: An up-Date. *Chem. Soc. Rev.* **2012**, *41* (1), 370– 939 412. 940
- (50) Hashmi, A. S. K. Dual Gold Catalysis. *Acc. Chem. Res.* **2014**, *47* 941 (3), 864–876. 942
- (51) Hogarth, G.; Alvarez-Falcon, M. M. Gold(I) Alkynyl 943 Complexes Derived from Ethynylanilines: Crystal Structure of 944 [Au(C≡C-4-C₆H₄NH₂){P(3-Tolyl)₃}] a Polymer in the Solid 945 State via NH...Au Contacts. *Inorg. Chim. Acta* **2005**, *358* (5), 1386– 946 1392. 947
- (52) Rodríguez, L.; Ferrer, M.; Crehuet, R.; Anglada, J.; Lima, J. C. 948 Correlation between Photophysical Parameters and Gold-Gold 949 Distances in Gold(I) (4-Pyridyl)Ethynyl Complexes. *Inorg. Chem.* 950 **2012**, *51* (14), 7636–7641. 951
- (53) Rejman, J.; Oberle, V.; Zuhorn, I. S.; Hoekstra, D. Size- 952 Dependent Internalization of Particles via the Pathways of Clathrin- 953 and Caveolae-Mediated Endocytosis. *Biochem. J.* **2004**, *377* (1), 159– 954 169. 955
- (54) dos Santos, T.; Varela, J.; Lynch, I.; Salvati, A.; Dawson, K. A. 956 Effects of Transport Inhibitors on the Cellular Uptake of 957

- 958 Carboxylated Polystyrene Nanoparticles in Different Cell Lines. *PLoS One* **2011**, *6* (9), e24438.
- 960 (55) Chen, M.; Yi, L.; Jin, X.; Xie, Q.; Zhang, T.; Zhou, X.; Chang, H.; Fu, Y.; Zhu, J.; Zhang, Q.; Mi, M.-T. Absorption of Resveratrol by Vascular Endothelial Cells through Passive Diffusion and an SGLT1-Mediated Pathway. *J. Nutr. Biochem.* **2013**, *24* (11), 1823–1829.
- 964 (56) Stehn, J. R.; Haass, N. K.; Bonello, T.; Desouza, M.; Kottyan, G.; Treutlein, H.; Zeng, J.; Nascimento, P. R. B. B.; Sequeira, V. B.; Butler, T. L.; Allanson, M.; Fath, T.; Hill, T. A.; McCluskey, A.; Schevzov, G.; Palmer, S. J.; Hardeman, E. C.; Winlaw, D.; Reeve, V. E.; Dixon, I.; Weninger, W.; Cripe, T. P.; Gunning, P. W. A Novel Class of Anticancer Compounds Targets the Actin Cytoskeleton in Tumor Cells. *Cancer Res.* **2013**, *73* (16), 5169–5182.
- 971 (57) Foerster, F.; Braig, S.; Moser, C.; Kubisch, R.; Busse, J.; Wagner, E.; Schmoeckel, E.; Mayr, D.; Schmitt, S.; Huettel, S.; Zischka, H.; Mueller, R.; Vollmar, A. M. Targeting the Actin Cytoskeleton: Selective Antitumor Action via Trapping PKC ϵ . *Cell Death Dis.* **2014**, *5* (8), e1398–e1398.
- 976 (58) Liu, W.; Gust, R. Update on Metal N-Heterocyclic Carbene Complexes as Potential Anti-Tumor Metallo-drugs. *Coord. Chem. Rev.* **2016**, *329*, 191–213.
- 979 (59) Suarez-Huerta, N.; Mosselmans, R.; Dumont, J. E.; Robaye, B. Actin Depolymerization and Polymerization Are Required during Apoptosis in Endothelial Cells. *J. Cell. Physiol.* **2000**, *184* (2), 239–245.
- 983 (60) Huang, T. C.; Toraya, H.; Blanton, T. N.; Wu, Y. X-Ray Powder Diffraction Analysis of Silver Behenate, a Possible Low-Angle Diffraction Standard. *J. Appl. Crystallogr.* **1993**, *26* (2), 180–184.
- 986 (61) Kieffer, J.; Karkoulis, D. PyFAL, a Versatile Library for Azimuthal Regrouping. *J. Phys.: Conf. Ser.* **2013**, *425* (20), 202012.
- 988 (62) Svergun, D. I. Determination of the Regularization Parameter in Indirect-Transform Methods Using Perceptual Criteria. *J. Appl. Crystallogr.* **1992**, *25* (4), 495–503.
- 991 (63) Svergun, D. I. Restoring Low Resolution Structure of Biological Macromolecules from Solution Scattering Using Simulated Annealing. *Biophys. J.* **1999**, *76* (6), 2879–2886.
- 994 (64) Kabe, R.; Adachi, C. Organic Long Persistent Luminescence. *Nature* **2017**, *550* (7676), 384–387.
- 996 (65) Xu, J.; Takai, A.; Kobayashi, Y.; Takeuchi, M. Phosphorescence from a Pure Organic Fluorene Derivative in Solution at Room Temperature. *Chem. Commun.* **2013**, *49* (76), 8447–8449.
- 999 (66) Zhou, G.-J.; Wang, X.-Z.; Wong, W.-Y.; Yu, X.-M.; Kwok, H.-S.; Lin, Z. New Platinum(II) Complexes as Triplet Emitters for High-Efficiency Monochromatic Pure Orange Electroluminescent Devices. *J. Organomet. Chem.* **2007**, *692* (16), 3461–3473.
- 1003 (67) Ferrer, M.; Mounir, M.; Rodríguez, L.; Rossell, O.; Coco, S.; Gómez-Sal, P.; Martín, A. Effect of the Organic Fragment on the Mesogenic Properties of a Series of Organogold(I) Isocyanide Complexes. X-Ray Crystal Structure of [Au(CCC5H4N)-(CNC6H4O(O)CC6H4OC10H21)]. *J. Organomet. Chem.* **2005**, *690* (9), 2200–2208.
- 1009 (68) Kishpaugh, D.; Hajagos, T.; Liu, C.; Chen, Q.; Pei, Q. Applications of Fluorene Moiety Containing Polymers for Improved Scintillation Light Yield. *Nucl. Instrum. Methods Phys. Res., Sect. A* **2017**, *868* (June), 59–65.
- 1013 (69) Baluja, S.; Kulshrestha, A.; Movalia, J. 1-Octanol-Water Partition Coefficient of Some Cyanopyridine and Chalcone Compounds. *Rev. Colomb. Cienc. Quim.-Farm.* **2017**, *46* (3), 342–356.
- 1016 (70) Czerwińska, K.; Machura, B.; Kula, S.; Krompiec, S.; Erfurt, K.; Roma-Rodrigues, C.; Fernandes, A. R.; Shul'Pina, L. S.; Ikonnikov, N. S.; Shul'Pin, G. B. Copper(II) Complexes of Functionalized 2,2':6',2''-Terpyridines and 2,6-Di(Thiazol-2-Yl)Pyridine: Structure, Spectroscopy, Cytotoxicity and Catalytic Activity. *Dalton Trans.* **2017**, *46* (29), 9591–9604.
- 1022 (71) Rodrigo, A. P.; Mendes, V. M.; Manadas, B.; Grosso, A. R.; Alves de Matos, A. P.; Baptista, P. V.; Costa, P. M.; Fernandes, A. R. Specific Antiproliferative Properties of Proteinaceous Toxin Secretions from the Marine Annelid *Eulalia* Sp. onto Ovarian Cancer Cells. *Mar. Drugs* **2021**, *19* (1), 31.